You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)稱目標最早2024年達收支平衡
阿思達克 06-30 13:02
和黃醫藥(00013.HK)今日(30日)在聯交所主板掛牌,公司首席執行官賀雋在記者會上表示,是次上市籌得的資金,加上早前公佈出售非處方藥合營,將使公司的現金資源增至達10億美元,令公司可捕捉更多潛在業務機會。

他指,公司每年將投資3億至3.5億美元在研發上,隨着多種藥品開始在中國及海外商業化,相信未來收入會持續增加並能抵銷研發等的投入,維持於2024至2025年達至收支平衡的目標。

公司是次在港上市約15%集資所得計劃用於潛在全球業務發展及策略收購機會,賀雋認爲需要多角度對抗癌症等疾病,對與旗下藥品資產有協同的合作持開放態度。至於非核心資產的處置,他稱會繼續尋求處理有關資產,但強調公司不急於出售,亦不會以低價出售。

他又指於香港上市後目前無計劃將股份在美國及英國市場除牌。而是次公司取得前和記黃埔上市編號「13」,賀雋稱此號碼有長久歷史,港交所亦等待有公司可再延續歷史,和黃醫藥對能夠參與此歷史感到自豪。(ek/a) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account